Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

Julia Foldi(University of Pittsburgh), Lajos Pusztai(Yale University)

npj Breast Cancer

February 8, 2021

10.1038/s41523-021-00219-7

Cited by 67

Related Papers

Pembrolizumab for Early Triple-Negative Breast Cancer

|New England Journal of Medicine|2020|3.1k

Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

|Journal of Clinical Oncology|2007|1.6k

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

|Annals of Oncology|2023|830

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

|Annals of Oncology|2018|774

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

|JAMA Oncology|2020|707